Literature DB >> 11511171

Metabonomic investigations into hydrazine toxicity in the rat.

A W Nicholls1, E Holmes, J C Lindon, J P Shockcor, R D Farrant, J N Haselden, S J Damment, C J Waterfield, J K Nicholson.   

Abstract

The systemic biochemical effects of oral hydrazine administration (dosed at 75, 90, and 120 mg/kg) have been investigated in male Han Wistar rats using metabonomic analysis of (1)H NMR spectra of urine and plasma, conventional clinical chemistry, and liver histopathology. Plasma samples were collected both pre- and 24 h postdose, while urine was collected predose and daily over a 7 day postdose period. (1)H NMR spectra of the biofluids were analyzed visually and via pattern recognition using principal component analysis. The latter showed that there was a dose-dependent biochemical effect of hydrazine treatment on the levels of a range of low molecular weight compounds in urine and plasma, which was correlated with the severity of the hydrazine induced liver lesions. In plasma, increases in the levels of free glycine, alanine, isoleucine, valine, lysine, arginine, tyrosine, citrulline, 3-D-hydroxybutyrate, creatine, histidine, and threonine were observed. Urinary excretion of hippurate, citrate, succinate, 2-oxoglutarate, trimethylamine-N-oxide, fumarate and creatinine were decreased following hydrazine dosing, whereas taurine, creatine, threonine, N-methylnicotinic acid, tyrosine, beta-alanine, citrulline, Nalpha-acetylcitrulline and argininosuccinate excretion was increased. Moreover, the most notable effect was the appearance in urine and plasma of 2-aminoadipate, which has previously been shown to lead to neurological effects in rats. High urinary levels of 2-aminoadipate may explain the hitherto poorly understood neurological effects of hydrazine. Metabonomic analysis of high-resolution (1)H NMR spectra of biofluids has provided a means of monitoring the progression of toxicity and recovery, while also allowing the identification of novel biomarkers of development and regression of the lesion.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511171     DOI: 10.1021/tx000231j

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  21 in total

1.  Metabolomic applications of electrochemistry/mass spectrometry.

Authors:  Paul H Gamache; David F Meyer; Michael C Granger; Ian N Acworth
Journal:  J Am Soc Mass Spectrom       Date:  2004-12       Impact factor: 3.109

2.  Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure.

Authors:  Sarah K Himes; Yanling Huo; George K Siberry; Paige L Williams; Mabel L Rice; Patricia A Sirois; Toni Frederick; Rohan Hazra; Marilyn A Huestis
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

3.  A statistical framework for biomarker discovery in metabolomic time course data.

Authors:  Maurice Berk; Timothy Ebbels; Giovanni Montana
Journal:  Bioinformatics       Date:  2011-07-15       Impact factor: 6.937

Review 4.  Metabolomics, pathway regulation, and pathway discovery.

Authors:  Guo-Fang Zhang; Sushabhan Sadhukhan; Gregory P Tochtrop; Henri Brunengraber
Journal:  J Biol Chem       Date:  2011-05-12       Impact factor: 5.157

5.  Metabolic Profiling of Human Blood by High Resolution Ion Mobility Mass Spectrometry (IM-MS).

Authors:  Prabha Dwivedi; Albert J Schultz; Herbert H Hill
Journal:  Int J Mass Spectrom       Date:  2010-12       Impact factor: 1.986

6.  Metabolic profiling of Escherichia coli by ion mobility-mass spectrometry with MALDI ion source.

Authors:  Prabha Dwivedi; Geoffery Puzon; Maggie Tam; Denis Langlais; Shelley Jackson; Kimberly Kaplan; William F Siems; Albert J Schultz; Luying Xun; Amina Woods; Herbert H Hill
Journal:  J Mass Spectrom       Date:  2010-12       Impact factor: 1.982

7.  CYP3A-mediated generation of aldehyde and hydrazine in atazanavir metabolism.

Authors:  Feng Li; Jie Lu; Laiyou Wang; Xiaochao Ma
Journal:  Drug Metab Dispos       Date:  2010-12-09       Impact factor: 3.922

Review 8.  Clinical applications of metabolomics in oncology: a review.

Authors:  Jennifer L Spratlin; Natalie J Serkova; S Gail Eckhardt
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Chemical and metabolomic screens identify novel biomarkers and antidotes for cyanide exposure.

Authors:  Anjali K Nath; Lee D Roberts; Yan Liu; Sari B Mahon; Sonia Kim; Justine H Ryu; Andreas Werdich; James L Januzzi; Gerry R Boss; Gary A Rockwood; Calum A MacRae; Matthew Brenner; Robert E Gerszten; Randall T Peterson
Journal:  FASEB J       Date:  2013-01-23       Impact factor: 5.191

10.  An integrated functional genomic study of acute phenobarbital exposure in the rat.

Authors:  Claire L Waterman; Richard A Currie; Lisa A Cottrell; Jacky Dow; Jayne Wright; Catherine J Waterfield; Julian L Griffin
Journal:  BMC Genomics       Date:  2010-01-06       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.